Image and quantify osteoporosis, arthritis, cancer metastases, and other bone diseases, as well as normal bone growth and resorption, in vivo with OsteoSense® Fluorescent Imaging probes. As opposed to other imaging modalities such as CT or x-ray which raise the risk of harmful irradiation to the subject, in vivo fluorescence imaging offers no radiation exposure concerns, and when performed with optimized hydroxyapatite-targeted probes such as OsteoSense, can image and quantify bone growth and elucidate the biology of bone remodeling.
OsteoSense is available in 3 wavelengths: 680, 750, and 800.
For laboratory use only. This product is intended for animal research only and not for use in humans.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
OsteoSense NIR fluorescent bisphosphonate imaging agents are designed to bind with high affinity to hydroxyapatite (HA) both in vivo and in vitro. Since HA is known to bind pyrophosphonates and phosphonates as well as synthetic bisphosphonates with high affinity, OsteoSense agents offer a safe and easy means to assess the subtle bone mineral changes that occur in bone growth, bone loss, and in diseases that damage bone, using subtherapeutic doses for imaging.
OsteoSense 680EX is excited by 668 ± 10 mn excitation light and emits at 687 ± 10 mn. Including OsteoSense 680EX in careful experimental design allows for multiplexing with other channels and/or imaging times, and so can be paired with other probes to achieve maximum efficiency and flexibility in imaging.
|Fluorescent Agent Type||Targeted|
|Optical Imaging Classification||Fluorescence Imaging|
|Product Brand Name||OsteoSense|
|Quantity in a Package Amount||1.0 Units|
|Therapeutic Area||Atherosclerosis, Arthritis, Oncology/Cancer|
|Unit Size||1 Vial (10 doses)|
|Wave Length||680 nm|
Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.
Imaging of Cathepsin K activity in rodent models of bone turnover and soft tissue calcification
The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.